Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 26,626 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Healthy
Interventions: GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: eneboparatide, Placebo; Combination Product
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more

Conditions: HIV/AIDS
Interventions: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM, DPBS Sucrose; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Seattle, Washington

Conditions: Anti Aging
Interventions: Vitality product AM + Vitality product PM, Placebo; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 35 Years to 73 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Orem, Utah

Conditions: Hemorrhoids
Interventions: EEA Hemorrhoid and Prolapse Stapling Set, Endosurgery Proximate PPH03 Stapling Set; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Migraine or Episodic Migraine
Interventions: Placebo, AMG 301; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Alzheimer's Disease
Interventions: T3D-959, Placebo Comparator; Drug · Other
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer Disease
Interventions: BMS-708163, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Migraine, Cannabis, THC
Interventions: THC ~2.5%, THC ~5%, THC ~10%, Sham Cannabis; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Allergic Asthma
Interventions: omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more

Conditions: Dercum's Disease Lipomas
Interventions: RZL-012, Vehicle; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Keratoconjunctivitis Sicca
Interventions: R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0%, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Hip Fracture, Blood Loss
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 90
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug; Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more

Conditions: Crohn's Disease
Interventions: OPS-2071, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 24
States / cities: Los Angeles, California • San Carlos, California • Colorado Springs, Colorado + 21 more

Conditions: Body Dysmorphic Disorder
Interventions: d-cycloserine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dementia, Alzheimer Type
Interventions: Xanamem™, Placebo (for Xanamem™); Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Poway, California + 11 more

Conditions: Orthodontic Discomfort, Pain, Orofacial
Interventions: 3M Unitek 0.016 orthodontic archwire, Device: 0.016" Ormco 27oC NiTi orthodontic archwire, Device: 0.016" Ormco 35oC NiTi orthodontic archwire; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Impulse Control Disorder, Parkinson Disease
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: oleoyl-estrone (MP 101); Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • Salt Lake City, Utah

Conditions: Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
Interventions: Estradiol vaginal cream; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Hypertension, Pregnancy-Induced, Hypertension
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions: Berobenatide, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Bradenton, Florida • Tomball, Texas

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women

Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Multiple Dose Japanese Bridging Study

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

RZL-012 for Dercum's Disease Lipomas

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Comparison of Patient-reported Pain After Initial Archwire Placement

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

Vaginal Estradiol Use in Pessary Care

Lasix for the Prevention of De Novo Postpartum Hypertension

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)